专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004029622A2 ANTIBODY TOOLS FOR THE DIAGNOSTIC USE IN THE MEDICAL THERAPY WITH INHIBITORS OF HISTONE DEACETYLASES 审中-公开
标题翻译：用于药物治疗的药物治疗用抗生素的工具与抗体脱乙酰壳多糖的抑制剂
公开(公告)号：WO2004029622A2
公开(公告)日：2004-04-08
申请号：PCT/EP0310842
申请日：2003-09-30
申请人： G2M CANCER DRUGS AG , PELICCI PIER GIUSEPPE , MINUCCI SAVERIO , PICCINI DANIELE , MACCARANA MARCO , RONZONI SIMONA , ARECES LILIANA BEATRIZ , FARETTA MARCO
发明人： PELICCI PIER GIUSEPPE , MINUCCI SAVERIO , PICCINI DANIELE , MACCARANA MARCO , RONZONI SIMONA , ARECES LILIANA BEATRIZ , FARETTA MARCO
IPC分类号： C07K16/18 , C12Q1/44 , G01N33/50
CPC分类号： C12Q1/44 , C07K16/18
摘要： The invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not comprising determining the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a reference sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.
摘要翻译：本发明涉及一种用于确定是否开始/继续使用HDAC抑制剂治疗病症的方法，包括通过使用能够结合乙酰化组蛋白的抗体来确定样品中组蛋白乙酰化的水平，并分类当组蛋白乙酰化水平显着低于参考样品的水平时，用HDAC抑制剂治疗的病症。本发明还涉及特异性抗体和产生它们的细胞系的诊断和预测性应用。

2. 发明专利

CA2500384A1 ANTIBODY TOOLS FOR THE DIAGNOSTIC USE IN THE MEDICAL THERAPYWITH INHIBITORS OF HISTONE DEACETYLASES 未知
公开(公告)号：CA2500384A1
公开(公告)日：2004-04-08
申请号：CA2500384
申请日：2003-09-30
申请人： G2M CANCER DRUGS AG
发明人： PELICCI PIER GIUSEPPE , ARECES LILIANA BEATRIZ , PICCINI DANIELE , MINUCCI SAVERIO , MACCARANA MARIO , FARETTA MARCO , RONZONI SIMONA
IPC分类号： C07K16/18 , C12Q1/44 , G01N33/50
摘要： The invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not comprising determining the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a reference sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.

3. 发明专利

AU2003271663A1 ANTIBODY TOOLS FOR THE DIAGNOSTIC USE IN THE MEDICAL THERAPY WITH INHIBITORS OF HISTONE DEACETYLASES 未知
公开(公告)号：AU2003271663A1
公开(公告)日：2004-04-19
申请号：AU2003271663
申请日：2003-09-30
申请人： G2M CANCER DRUGS AG
发明人： MACCARANA MARCO , RONZONI SIMONA , ARECES LILIANA BEATRIZ , FARETTA MARCO , PELICCI PIER GIUSEPPE , MINUCCI SAVERIO , PICCINI DANIELE
IPC分类号： C07K16/18 , C12Q1/44 , G01N33/50
摘要： Determining (M1) whether treatment of disorder with histone deacetylase (HDAC) inhibitor is to be started/continued/not by contacting sample from tissue affected by disorder with antibody binding to acetylated histone but not to deacetylated histone, determining histone level acetylation in sample and classifying disorder as to be treated with HDAC inhibitor when histone acetylation level is significantly less than control sample. Independent claims are also included for: (1) use of an antibody capable of binding to acetylated histone for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not, and/or the classification of tumors; (2) an antibody (I) capable of binding to peptides having a sequence of Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys- Arg (histone H4 tail, mono-acetylated at lysine 8) (S1) and Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys- Arg (histone H4 tail, mono-acetylated at lysine 12) (S2) but not to anyone of the peptides having the sequences of Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys- Arg (histone H4 tail, mono-acetylated at lysine 16) (S3), Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys- Arg (non-acetylated peptide) (S4), Ala-Val-Cys-Asp-Lys-Cys-Leu-Lys-Phe-Tyr-Ser-Lys and Val-Trp-Asp-Gln-Glu-Phe-Leu-Lys-Val-Asp-Gln-Gly; (3) an antibody (II) capable of binding to peptides having (S1), (S2) and (S3) but not to peptides having (S4); (4) an antibody produced by a hybridoma cell line chosen from hybridoma cell lines G2M-T25-H4ac and G2M-T52-ac deposited at DSMZ; (5) a hybridoma cell line producing (I) or (II); (6) a hybridoma cell line which has the identifying characteristics of the cell line G2M-T25-H4ac deposited at DSMZ; (7) a hybridoma cell line which has the identifying characteristics of the cell line G2M-T52-ac deposited at DSMZ; (8) a diagnostic kit (III) for determining the level of histone acetylation containing an antibody capable of binding to acetylated histone but not to deacetylated histone, an HDAC inhibitor, and optionally, a secondary antibody directed against the antibody, and optionally reagents for the measurement of a signal derived from an antibody binding to acetylated histones; and (9) use of the antibodies T25 and/or T52 (IV) to direct substances conjugated to these antibodies to sites of histone hyperacetylation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式